Oral Cleft Prevention Program
Primary Purpose
Cleft Lip, Cleft Palate
Status
Completed
Phase
Phase 3
Locations
United States
Study Type
Interventional
Intervention
Folic acid: 4 mg versus 0.4 mg per day
Sponsored by
About this trial
This is an interventional prevention trial for Cleft Lip
Eligibility Criteria
Inclusion Criteria:
- Women with cleft lip with/out palate (CLP), 16 to 45 years of age registered at the study clinics in Brazil or Women (16 to 45 years of age) with at least one natural child of any age with CLP registered at the study clinics.
- Women must reside in the catchment area of the study, which includes the states where the study clinics are located and surrounding states.
Exclusion Criteria:
- Consanguineous couples (up to third degree, i.e. first cousins or closer).
- Pregnany at the time of recruitment. Women will be recontacted later at an appropriate time for participation in the study.
- Couples either one of which have been sterilized.
- Taking any form of seizure medication.
- Planning to move outside of the study catchment area within the next year.
- B12 deficiency (<174 pg/mL or 129.15 pmol/L).
- Being allergic to folic acid.
Sites / Locations
- University of Iowa
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
Active Comparator
Arm Label
400 micrograms of folic acid
4mg of folic acid
Arm Description
Blinded study with two arms one of 400ug in arm 1
Second arm is 4mg of folic acid in arm 2
Outcomes
Primary Outcome Measures
Recurrence of cleft lip and palate
Secondary Outcome Measures
Full Information
NCT ID
NCT00397917
First Posted
November 8, 2006
Last Updated
March 30, 2017
Sponsor
University of Iowa
Collaborators
National Institute of Dental and Craniofacial Research (NIDCR), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), RTI International, University of Sao Paulo
1. Study Identification
Unique Protocol Identification Number
NCT00397917
Brief Title
Oral Cleft Prevention Program
Official Title
Oral Cleft Prevention Program
Study Type
Interventional
2. Study Status
Record Verification Date
March 2017
Overall Recruitment Status
Completed
Study Start Date
November 2006 (undefined)
Primary Completion Date
May 2012 (Actual)
Study Completion Date
July 2013 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University of Iowa
Collaborators
National Institute of Dental and Craniofacial Research (NIDCR), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), RTI International, University of Sao Paulo
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
The purpose of this study is to asses if taking 4 mg of folic acid per day at preconception and during the first three months of pregnancy decreases the risk of having a child with cleft lip and palate compared to 0.4 mg folic acid for women who have an oral cleft or have had previously child with an oral cleft.
Detailed Description
Cleft lip and palate is a common and burdensome birth defect that has large health ramifications and requires surgical, speech, behavioral, dental, and medical interventions. There is some evidence suggesting that taking folic acid particularly at large doses during preconception and first trimester of pregnancy may decrease the risk of oral cleft recurrence, which is the risk of having a child with an oral cleft for women who have an oral cleft or who have had a child with a cleft. However this evidence is based on study designs that are incapable of contributing the preventive effects to folic acid with adequate confidence, and the real effect of folic acid on cleft recurrence prevention remains to be identified. Taking 4 mg of folic acid per day at preconception and first trimester of pregnancy has also been shown to prevent the recurrence of neural tube defects by up to 70%, providing further support to evaluate this intervention for oral cleft recurrence.
This study evaluates the effects of supplementation with 4 versus 0.4 mg of folic acid per day at preconception and during the first three months of pregnancy on recurrence of cleft lip and palate. Up to 6000 women will be randomly assigned to 4 versus 0.4 mg groups. The primary aim is to compare the recurrence rates in the offspring of trial mothers in the two groups. Secondary aims are to compare the two groups on several outcomes including miscarriage, twinning, pre-eclampsia, serum and red cell folate levels, severity of oral clefts and occurrence of other birth defects in the offspring of trial mothers, and birth weight and gestational age of trial babies, and to compare the recurrence in the two groups to that in historic controls.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Cleft Lip, Cleft Palate
7. Study Design
Primary Purpose
Prevention
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Masking Description
Random number assignments
Allocation
Randomized
Enrollment
4000 (Actual)
8. Arms, Groups, and Interventions
Arm Title
400 micrograms of folic acid
Arm Type
Active Comparator
Arm Description
Blinded study with two arms one of 400ug in arm 1
Arm Title
4mg of folic acid
Arm Type
Active Comparator
Arm Description
Second arm is 4mg of folic acid in arm 2
Intervention Type
Drug
Intervention Name(s)
Folic acid: 4 mg versus 0.4 mg per day
Intervention Description
Folic acid
Primary Outcome Measure Information:
Title
Recurrence of cleft lip and palate
Time Frame
3 months
10. Eligibility
Sex
Female
Minimum Age & Unit of Time
16 Years
Maximum Age & Unit of Time
45 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Women with cleft lip with/out palate (CLP), 16 to 45 years of age registered at the study clinics in Brazil or Women (16 to 45 years of age) with at least one natural child of any age with CLP registered at the study clinics.
Women must reside in the catchment area of the study, which includes the states where the study clinics are located and surrounding states.
Exclusion Criteria:
Consanguineous couples (up to third degree, i.e. first cousins or closer).
Pregnany at the time of recruitment. Women will be recontacted later at an appropriate time for participation in the study.
Couples either one of which have been sterilized.
Taking any form of seizure medication.
Planning to move outside of the study catchment area within the next year.
B12 deficiency (<174 pg/mL or 129.15 pmol/L).
Being allergic to folic acid.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Jeffrey Murray, MD
Organizational Affiliation
University of Iowa
Official's Role
Principal Investigator
Facility Information:
Facility Name
University of Iowa
City
Iowa City
State/Province
Iowa
ZIP/Postal Code
52242
Country
United States
12. IPD Sharing Statement
Plan to Share IPD
No
IPD Sharing Plan Description
Individual level data will not be shared unless de-identified
Citations:
PubMed Identifier
23669628
Citation
Vila-Nova C, Wehby GL, Queiros FC, Chakraborty H, Felix TM, Goco N, Moore J, Gewehr EV, Lins L, Affonso CM, Murray JC. Periconceptional use of folic acid and risk of miscarriage - findings of the Oral Cleft Prevention Program in Brazil. J Perinat Med. 2013 Jul;41(4):461-6. doi: 10.1515/jpm-2012-0173.
Results Reference
result
PubMed Identifier
23181832
Citation
Wehby GL, Goco N, Moretti-Ferreira D, Felix T, Richieri-Costa A, Padovani C, Queiros F, Guimaraes CV, Pereira R, Litavecz S, Hartwell T, Chakraborty H, Javois L, Murray JC. Oral cleft prevention program (OCPP). BMC Pediatr. 2012 Nov 26;12:184. doi: 10.1186/1471-2431-12-184.
Results Reference
derived
Learn more about this trial
Oral Cleft Prevention Program
We'll reach out to this number within 24 hrs